257: Cardiovascular risk prevalence in high risk primary care patients not treated with lipid-lowering treatment in France, results of an online study

Abstract

Few data exists on high cardiovascular risk (HCVR) prevalence within a primary prevention population. The goal of the study was to assess HCVR distribution, according to SCORE, in France for high-risk primary care patients not treated with lipid-lowering drug. This observational study was conducted over a week on a representative sample of French general practitioners (GP). All consulting primary care men/women ≥50/60 y, with at least one other CVR factor (smoking, high blood pressure (HBP), type 2 diabetes, HDL-c<0.40 g/L), not treated for dyslipidemia were included in the study. GP filled-in an on line questionnaire that enabled SCORE calculation. GPs (n=1147) included 9049 patients with the following characteristics: mean age: 68 y; male: 57%; LDLc>1.3 g/L: 57%; smoking: 21%; HBP: 44%; type 2 diabetes: 21% HDL-c<0.4 g/L: 16%. According to SCORE, HCVR prevalence reached 50% in total population (male: 49%, female: 51%). 50% of HCVR men/women were older than >72.4/78.8 y. HCVR patients were older by 7.7/6.8 y for male/female (p <0.01) than non-HCVR patients. Other significantly more frequent characteristics in high CVR population are: HDL≥0.6 g/L (38%), untreated or uncontrolled HBP (53%) and left ventricular hypertrophy (8%). Obesity is less frequent (15%) in high CVR population. Highest HCVR prevalence was observed in the Mediterranean population (54%), and lowest (47%) in the Northeast population (p <0.01). Adjustment by age and gender reduces regional disparities between regions (52% vs 48%). Half consulting primary care patients aged ≥50/60 y for men/women with at least 1 risk factor on top of age and no lipid-lowering treatment are at HCVR according to SCORE risk equation. Assessing cardiovascular risk with risk equations appears particularly useful in this group of patients. Besides age, which has the strongest impact on risk estimation, other RF may be screened to improve HCVR management.